Combination Therapy with Famotidine and Pantoprazole

Pharmacologic Rationale

• Different mechanisms of action allow for complementary effects: Famotidine (an H2-receptor antagonist) and pantoprazole (a proton pump inhibitor) work through distinct pathways to suppress gastric acid secretion, making them pharmacologically compatible 1
• No significant drug-drug interactions exist between these agents: PPIs and H2-receptor antagonists do not share metabolic pathways that would create clinically meaningful interactions 2
• Dose equivalency matters: Famotidine 20 mg twice daily is considered equivalent to pantoprazole 40 mg once daily in standard dosing 1

Combination Therapy with Famotidine and Pantoprazole

Pharmacologic Compatibility

• The American College of Cardiology notes that H2 blockers, such as famotidine, do not interfere with other drug mechanisms, unlike some PPIs that inhibit CYP2C19, allowing for safe combination therapy with pantoprazole 3, 4, 5

Clinical Evidence Supporting Combination Use

• In critical care settings, guidelines recommend using both famotidine and pantoprazole as part of treatment protocols for managing infusion reactions and gastrointestinal prophylaxis, with dosing options including famotidine 20 mg IV and pantoprazole 40 mg PO/IV daily 6, 7